107 related articles for article (PubMed ID: 6205740)
1. Interferon activity and its characterization in the sera of patients with head and neck cancer.
Sato M; Yoshida H; Yanagawa T; Yura Y; Urata M; Atsumi M; Furumoto N; Hayashi Y; Takegawa Y
Cancer; 1984 Oct; 54(7):1239-51. PubMed ID: 6205740
[TBL] [Abstract][Full Text] [Related]
2. Interferon activity and its characterization in the sera of patients with premalignant lesions arising in oral mucosa.
Urata M; Yoshida H; Yanagawa T; Yura Y; Furumoto N; Azuma M; Hayashi Y; Sato M
Int J Oral Maxillofac Surg; 1986 Apr; 15(2):134-47. PubMed ID: 2420904
[TBL] [Abstract][Full Text] [Related]
3. Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer.
Sato M; Yoshida H; Yanagawa T; Yura Y; Urata M; Atsumi M; Hayashi Y; Takegawa Y
Int J Oral Surg; 1984 Feb; 13(1):7-15. PubMed ID: 6203858
[TBL] [Abstract][Full Text] [Related]
4. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
5. High interferon titer and defective NK-cell activity in the circulation of nasopharyngeal carcinoma patients.
Lakhdar M; Oueslati R; Ellouze R; Thameur H; Cammoun M; Khedhiri N; Kastally R
Int J Cancer; 1989 Apr; 43(4):543-8. PubMed ID: 2539326
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulin levels in patients with head and neck cancer (IgE, IgA, IgM, IgG).
Vinzenz K; Pavelka R; Schönthal E; Zekert F
Oncology; 1986; 43(5):316-22. PubMed ID: 3763126
[TBL] [Abstract][Full Text] [Related]
7. Peripheral K-lymphocyte population in head and neck cancer.
Hayashi Y; Nishida T; Yoshida H; Yanagawa T; Yura Y; Nitta T; Sato M
Cancer; 1984 Jun; 53(11):2507-14. PubMed ID: 6608986
[TBL] [Abstract][Full Text] [Related]
8. Interferon and beta 2-microglobulin in patients with common variable immunodeficiency or selective IgA deficiency.
Strannegård O; Björkander J; Hellstrand K; Pacsa A; Hermodsson S; Hanson LA
Int Arch Allergy Appl Immunol; 1987; 84(3):217-22. PubMed ID: 2443457
[TBL] [Abstract][Full Text] [Related]
9. Detection of gamma interferon in the sera of patients with Behçet's disease.
Ohno S; Kato F; Matsuda H; Fujii N; Minagawa T
Infect Immun; 1982 Apr; 36(1):202-8. PubMed ID: 6176541
[TBL] [Abstract][Full Text] [Related]
10. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
11. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of interferon-gamma on squamous-cell carcinoma of head and neck targets in antibody-dependent cellular cytotoxicity mediated by human natural killer cells.
Sung MW; Johnson JT; Van Dongen G; Whiteside TL
Int J Cancer; 1996 May; 66(3):393-9. PubMed ID: 8621263
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
14. Distribution of circulating natural killer cells and T lymphocytes in head and neck squamous cell carcinoma.
Böttcher A; Ostwald J; Guder E; Pau HW; Kramp B; Dommerich S
Auris Nasus Larynx; 2013 Apr; 40(2):216-21. PubMed ID: 22835730
[TBL] [Abstract][Full Text] [Related]
15. The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation.
Novick D; Nabioullin RR; Ragsdale W; McKenna S; Weiser W; Garone L; Burkins C; Kim SH; Rubinstein M; Tepper MA; Arulanandam AR
J Interferon Cytokine Res; 2000 Nov; 20(11):971-82. PubMed ID: 11096454
[TBL] [Abstract][Full Text] [Related]
16. Circulating interferon in human autoimmune diseases.
Hooks JJ; Moutsopoulos HM; Notkins AL
Tex Rep Biol Med; 1981-1982; 41():164-8. PubMed ID: 6184802
[TBL] [Abstract][Full Text] [Related]
17. Interferon system of human cornea cells: interferon production, characterization, and development of antiviral state.
Thacore HR; Mount DT; Chadha KC
J Interferon Res; 1982; 2(3):401-8. PubMed ID: 6182255
[TBL] [Abstract][Full Text] [Related]
18. The relationship of circulating IgA to cellular immunity in head and neck cancer patients.
Schantz SP; Liu FJ; Taylor D; Beddingfield N; Weber RS
Laryngoscope; 1988 Jun; 98(6 Pt 1):671-8. PubMed ID: 3259661
[TBL] [Abstract][Full Text] [Related]
19. An immunologic profile of young adults with head and neck cancer.
Schantz SP; Liu FJ
Cancer; 1989 Sep; 64(6):1232-7. PubMed ID: 2569924
[TBL] [Abstract][Full Text] [Related]
20. Presence of interferon in acute- and convalescent-phase sera of humans with influenza or influenza-like illness of undetermined etiology.
Green JA; Charette RP; Yeh TJ; Smith CB
J Infect Dis; 1982 Jun; 145(6):837-41. PubMed ID: 6177804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
